Ibrutinib treatment for chronic lymphocytic leukemia with the deletion of chromosome 17p (del17p CLL) increases the percentage of patients alive at 30 months over other therapies for del17p CLL, study findings presented at the European Hematology Association 21st Congress have shown: oncologynurseadvisor.com/le...
'This study analyzed data from 243 patients with del17p CLL from 3 different ibrutinib clinical trials. Half of the patients received ibrutinib for 28 months or longer. The overall response rate was 84%. Progression-free survival at 30 months was estimated at 55%, and overall survival was 67% at 30 months.'
Neil
Photo: White Eared honeyeater